Medical Necessity Assessment for Truxima (Rituximab-abbs) in Rheumatoid Arthritis

Standard of Care Status

The European League Against Rheumatism (EULAR) guidelines explicitly include rituximab as a recommended biologic DMARD option for patients with inadequate response to conventional synthetic DMARDs, particularly after TNF inhibitor failure 1
The American College of Rheumatology recognizes rituximab as standard therapy with high-quality evidence supporting its use in this population, although the specific guideline is not cited here, Mayo Clinic treatment algorithms position rituximab as a standard option for patients beyond 6-12 months who have not achieved treatment targets with conventional DMARDs 2, 3

EULAR guidelines acknowledge that some patients require biologic monotherapy when conventional DMARDs cannot be tolerated, as in the case of this patient who cannot tolerate methotrexate 1, 2

A Cochrane review of rituximab in rheumatoid arthritis found no significant increase in serious adverse events at 48-56 weeks or 104 weeks follow-up, indicating a favorable safety profile 4

Discontinuing effective therapy in a patient with established response would risk disease flare, joint damage progression, and functional decline, according to the European League Against Rheumatism (EULAR) guidelines 1

The American College of Rheumatology and Mayo Clinic guidelines suggest that rituximab is a standard of care option for patients with moderately- to severely-active rheumatoid arthritis who have had an inadequate response to at least one TNF antagonist therapy, with a strength of evidence rated as high 5, 6
Patients with rheumatoid factor positive, antibodies to citrullinated protein, or increased serum IgG concentration demonstrate a particularly favorable response to rituximab, according to Mayo Clinic guidelines 5, 6
For seronegative patients with inadequate TNF response, Mayo Clinic guidelines suggest considering abatacept or tocilizumab as potentially more effective alternatives 5, 6

Each treatment course of rituximab should be evaluated for efficacy over 3-6 months before determining response, as recommended by Mayo Clinic guidelines 5, 6

Glucocorticoids, such as methylprednisolone, are appropriate as adjunctive therapy in rheumatoid arthritis for disease control, particularly when used at physiologic doses rather than supraphysiologic doses, according to the 2022 ACR/AAHKS guidelines 7
The 2022 ACR/AAHKS guidelines recommend continuing current daily doses of glucocorticoids for rheumatic conditions 7